Oxurion NV Stock price

Equities

OXUR

BE0003846632

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 12:35:05 2024-03-18 pm EDT 5-day change 1st Jan Change
0.0001 EUR 0.00% Intraday chart for Oxurion NV -66.67% -88.89%
Sales 2021 1.13M 1.23M Sales 2022 595K 647K Capitalization 7.81M 8.49M
Net income 2021 -29M -31.53M Net income 2022 -31M -33.7M EV / Sales 2021 64.8 x
Net Debt 2021 2.11M 2.3M Net Debt 2022 4.42M 4.81M EV / Sales 2022 20.6 x
P/E ratio 2021
-2.39 x
P/E ratio 2022
-0.05 x
Employees 20
Yield 2021 *
-
Yield 2022
-
Free-Float 56.31%
More Fundamentals * Assessed data
Dynamic Chart
1 week-50.00%
Current month-50.00%
1 month-66.67%
3 months-88.89%
6 months-92.86%
Current year-88.89%
More quotes
1 week
0.00
Extreme 0.0001
0.00
1 month
0.00
Extreme 0.0001
0.00
Current year
0.00
Extreme 0.0001
0.00
1 year
0.00
Extreme 0.0001
0.01
3 years
0.00
Extreme 0.0001
2.83
5 years
0.00
Extreme 0.0001
6.78
10 years
0.00
Extreme 0.0001
24.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - Dec. 27
Corporate Secretary - 20-02-29
General Counsel - -
Members of the board TitleAgeSince
Director/Board Member 64 23-03-13
Director/Board Member 58 Dec. 27
Director/Board Member - 23-03-13
More insiders
Date Price Change Volume
24-03-18 0.0001 0.00% 32,327,010
24-03-15 0.0001 -50.00% 66,385,810
24-03-14 0.0002 0.00% 35,641,820
24-03-13 0.0002 +100.00% 56,161,830
24-03-12 0.0001 -66.67% 82,931,440

Real-time Euronext Bruxelles, March 18, 2024 at 12:35 pm EDT

More quotes
Oxurion NV is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide. Oxurion NV is aiming to build the leading global franchise in the treatment of DME, based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all DME patients.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Oxurion NV - Euronext Bruxelles